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Bioactivity studyAbstract New polysubstituted N-arylpyrazole derivatives were synthesized from N1-arylsydnone
with acetylene and boronic acid, including 2-thiophenyl, 3-thiophenyl, 2-benzo[b]thiophenyl, or dib-
enzothiophenyl-4-boronic acid, via 1,3-dipolar cycloaddition and Suzuki coupling reaction. Based
on the growth inhibitory activity results against lung carcinoma (NCI-H226), nasopharyngeal
(NPC-TW01), and T-cell leukemia (Jurkat) cancer cells, compounds 5d and 7d with dibenzothi-
ophenyl bioisostere possessed the signiﬁcant inhibitory activity for NPC-TW01 (32 lM and
16 lM) and NCI-H226 (16 lM and 8.9 lM), respectively.
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pyrazole-containing compounds exhibit signiﬁcant biological
properties such as anti-cancer (Bandgar et al., 2010;Puthiyapurayil et al., 2012; Sun et al., 2013; Sangani et al.,
2014), antihyperglycemic, analgesic, anti-inﬂammatory
(Bandgar et al., 2010), antipyretic, antibacterial (Sangani
et al., 2014), anticonvulsant, antidepressant, hypoglycemic,
gastric secretion stimulatory, sedative-hypnotic activities
(Stauffer et al., 2000, 2001; Baraldi et al., 2005; Singh et al.,
2006). For example, several members of pyrazole-contained
bioactive molecules were manufactured as the lead compounds
or commercial drugs such as Ethiprol (Vidau et al., 2009),
Fipronil (Vidau et al., 2009), Pyrazofurin (Olah et al., 1980),
and Ribavirin (Manns et al., 2001). Recent investigation incor-
porated a pyrazole core in A2A receptor antagonists, CB1
receptor antagonists, DNA intercalating agents, and estrogen
receptor ligands (Baraldi et al., 2003; Pastorin et al., 2003;
Lauria et al., 2008; Slee et al., 2008; Wang et al., 2008;Journal
2 N. Uramaru et al.Fustero et al., 2009; Kawashita and Hayashi, 2009; Romanelli
and Autino, 2009). Thus, the modiﬁed pyrazole compounds
have often offered the ﬂexibility for design and construction
of the structural analogs of biomedical interest and also are
considered as the attractive targets for organic synthesis.
Heterocycles often seemed to be perfect bioisosteres;
accordingly they can deliver equal or even better biological efﬁ-
cacy through their similarity in structural shape and electronic
distribution (Sagara et al., 1995; Sharma et al., 2011). Based on
the facts, the fused thiophene (Arroyo and Salas-Puig, 2001;
Noguchi et al., 2004; Molvi et al., 2007; Ashalatha et al.,
2007; Rai et al., 2008) and benzothiophene (Connor et al.,
1992; Boschelli et al., 1994, 1995; Butera et al., 1995) moiety
became the great potential subject of interest (Ashalatha
et al., 2007; Rai et al., 2008; Roman, 2015; Sharma et al.,
2011; Tu et al., 2014). For example, presently available active
antiepileptic drugs (AEDs) such as tiagabine (Arroyo and
Salas-Puig, 2001), etizolam (Polivka et al., 1984) and brotizo-
lam (Noguchi et al., 2004) contain thiophene moiety in their
structures. On the other hand, the fused benzothiophene deriv-
atives have been shown to exert both anti-inﬂammatory and
anti-HIV effects (Critchﬁeld et al., 1997). PD144795, a new
fused benzothiophene derivative, can block the adhesion of
neutrophils to human umbilical vein endothelial cells and inhi-
bit the expression of both E-selectin and ICAM-1 molecules
(Carballo et al., 2002). Furthermore, the speciﬁc benzothio-
phene-substituted oxime ether strobilurins possessed the potent
exhibition of fungicidal activities at a concentration of 0.39 mg/
L compared to Enoxastrobin (Tu et al., 2014).
The goal of this work was to prepare a series of polysubsti-
tuted N-arylpyrazole derivatives utilizing thiophenyl and ben-
zothiophene as bioisostere for investigating the attractive
structural targets. Based on the structure–activity study and
the biological assay, compounds 5d and 7d with dibenzothi-
ophenyl moiety were indicated that they possessed the signiﬁ-
cant inhibitory activity for NPC-TW01 and NCI-H226 two
cancer cells.2. Experimental
2.1. Material and physical measurements
2.1.1. General procedure
All chemicals were reagent grade and used as purchased. All
reactions were carried out under nitrogen atmosphere and
monitored by TLC. Flash column chromatography was car-
ried out on silica gel (230–400 mesh). Toluene and p-xylene
were purchased fromMerck Chemical Co., and Dichlorometh-
ane, chloroform, tetrahydrofuran, ethanol and methanol were
purchased from Fluka & Aldrich. Phenylacetylene, diphenyl-
acetylene, 2-thiopheneboronic acid, 3-thiopheneboronic acid,
2-benzothienylboronic acid and dibenzothiophene-4-boronic
acid were purchased from Arcos Chemical Co., Potassium car-
bonate was purchased from TCI Chemical Co., Infrared (IR)
spectra were measured on a Bomem Michelson Series FT-IR
spectrometer. The wavenumbers reported are referenced to
the polystyrene 1601 cm1 absorption. Absorption intensities
are recorded by the following abbreviations: s, strong; m, med-
ium; w, weak. UV–visible spectra were measured with a HP
8452A diode-array spectrophotometer. Photoluminescence
(PL) spectra were obtained on a Perkin-Elmer ﬂuorescencePlease cite this article in press as: Uramaru, N. et al., Synthesis and evaluation of in v
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obtained on a Bruker AC-300 (300 MHz) spectrometer by
the use of DMSO-d6 as the solvent. Carbon-13 NMR spectra
were obtained on a Bruker AC-300 (75 MHz) spectrometer
by using DMSO-d6 as solvent. Carbon-13 chemical shifts are
referenced to the center of the DMSO-d6 sextet (d 39.6 ppm).
Multiplicities are recorded by the following abbreviations: s,
singlet; d, doublet; t, triplet; q, quartet; m, multiplet; J, cou-
pling constant (hertz). Elemental analyses were carried out
on a Heraeus CHN–O RAPID element analyzer.
2.2. Standard procedure for synthesis of pyrazoles (2, 3 and 4)
via 1,3-dipolar cyclization
A solution of 3-arylsydnone (1a or 1b, 0.20 g, 1.0 equiv) in
4 mL p-xylene was added with acetylene, including phenylacet-
ylene, diphenylacetylene, or 1-bromo-4-ethynylbenzene (1.05
equiv) and heated to reﬂux for 24 h. When the reaction was
completed, the reaction mixture was concentrated under
reduced pressure to remove p-xylene. The residue solution
was puriﬁed by column chromatography on silica gel (elution
with 30:70 EtOAc/hexane) to give the corresponding pyrazoles
2, 3, and 4 in 71% (Rf = 0.28), 47% (Rf = 0.26), 74%
(Rf = 0.26) isolated yields. Another minor regioisomer of
compounds 2 and 4 was also obtained in 11% (Rf = 0.32)
and 12% (Rf = 0.30) yields, respectively (Chang et al., 2006;
Foster et al., 2011, 2012).
2.2.1. 1-(4-Bromophenyl)-3-phenyl-1H-pyrazole (2)
1H NMR (CDCl3, 300 MHz) d 6.78 (d, J= 2.4 Hz, 1H, ArH),
7.36 (t, J= 7.2 Hz, 1H, ArH), 7.44 (t, J= 7.5 Hz, 2H, ArH),
7.57 (d, J= 8.7 Hz, 2H, ArH), 7.67 (d, J= 8.7 Hz, 2H, ArH),
7.90–7.92 (m, 3H, ArH); 13C NMR (CDCl3, 75 MHz) d 105.4,
119.4, 120.3, 125.8, 127.8, 128.2, 128.7, 132.4, 132.8, 139.1,
153.2; FABMS m/z (%): 300 (M++H, 100), 299 (M+, 66)
Anal. Calcd for C15H11BrN2; C: 60.22; H: 3.71; N: 9.36; found:
C: 60.21; H: 3.67; N: 9.39.
2.2.2. 1-(4-Bromophenyl)-3,4-diphenyl-1H-pyrazole (3)
1H NMR (CDCl3, 300 MHz) d 7.33–7.35 (m, 8H, ArH), 7.57–
7.61 (m, 4H, ArH), 7.69 (d, J= 8.8 Hz, 2H, ArH), 7.99 (s, 1H,
ArH); 13C NMR (CDCl3, 75 MHz); d 119.6, 120.2, 123.4,
126.4, 127.1, 128.1, 128.3, 128.4, 128.5, 128.7, 132.4, 132.5,
132.8, 138.9, 150.8; FABMS m/z (%): 376 (M+ +H, 100),
375 (M+, 72); Anal. Calcd for C21H15BrN2; C: 67.21; H:
4.03; N: 7.47; found: C: 67.23; H: 4.02; N:7.45.
2.2.3. 3-(4-Bromophenyl)-1-phenyl-1H-pyrazole (4)
1H NMR (CDCl3, 300 MHz) d 6.73 (d, J= 2.9 Hz, 1H, ArH),
7.30 (t, J= 7.2 Hz, 1H, ArH), 7.47 (t, J= 7.5 Hz, 2H, ArH),
7.56 (d, J= 8.1 Hz, 2H, ArH), 7.74–7.81 (m, 4H, ArH), 7.93
(d, J= 3.0 Hz, 1H, ArH); 13C NMR (CDCl3, 75 MHz) d
104.9, 119.0, 121.9, 126.5, 127.3, 128.1, 129.4, 131.7, 132.0,
140.0, 151.7; FABMS m/z (%): 300 (M++H, 100), 299
(M+,36); Anal. Calcd for C15H11BrN2; C: 60.22; H: 3.71; N:
9.36; found: C: 60.18; H: 3.72; N: 9.37.
2.3. Synthesis of fused-thiophenyl/phenylpyrazoles 5a–d, 6a–d,
and 7a–d via palladium(0)-catalyzed cross-coupling reaction
Amixture of 1,3-diaryl-1H-pyrazoles (2, 3, or 4, 5.46 mmol, 1.0
equiv), fused-thiophenyl-2-boronic acid (8.20 mmol, 2.0 equiv),itro bioactivity for polysubstituted N-arylpyrazole derivatives. Arabian Journal
Table 1 The results of synthesis of polysubstituted N-arylpyrazole derivatives 5a–d, 6a–d, and 7a–d.
Pyrazoles Boronic acid RB(OH)2 Polysubstituted N-arylpyrazole
No. X Y Z R No. Yields (%)
2 Br H H 2-Thiophenyl 5a 82
2 Br H H 3-Thiophenyl 5b 85
2 Br H H 2-Benzo[b]thio-phenyl 5c 79
2 Br H H Dibenzothio-phenyl 5d 81a
3 Br Ph H 2-Thiophenyl 6a 85
3 Br Ph H 3-Thiophenyl 6b 87
3 Br Ph H 2-Benzo[b]thio-phenyl 6c 76
3 Br Ph H Dibenzothio-phenyl 6d 72
4 H H Br 2-Thiophenyl 7a 81
(continued on next page)
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Table 1 (continued)
Pyrazoles Boronic acid RB(OH)2 Polysubstituted N-arylpyrazole
4 H H Br 3-Thiophenyl 7b 88
4 H H Br 2-Benzo[b]thio-phenyl 7c 80
4 H H Br Dibenzothio-phenyl 7d 83a
a Characterization data for compounds 5d and 7d were shown in reference (Roman G. 2015).
4 N. Uramaru et al.tetrakis(triphenylphosphine)palladium (0.199 mmol, 0.037
equiv), potassium carbonate (8 ml of 2 M aq. solution;
16.0 mmol, 3.0 equiv), and p-xylene/EtOH (40/20 ml) was
heated under stirring to reﬂux for 24 h in nitrogen atmosphere.
The mixture was concentrated, added with water (10 ml), and
extracted with dichloromethane (3 · 50 ml). The combined
organic solution was washed with a saturated aqueous sodium
hydrogen carbonate solution (20 ml), brine (20 ml), dried with
anhydrous magnesium sulfate and evaporated. The residue
was puriﬁed by column chromatography (silica gel, elution with
hexane), and fractions containing the product were collected
and evaporated. Crystallization from ethyl acetate/EtOH affor-
ded the corresponding fused thiophenyl/phenylpyrazole and
benzothiophene/phenylpyrazole products 5a–d, 6a–d, and 7a–d.
2.3.1. 3-Phenyl-1-(4-(thiophen-2-yl)phenyl)-1H-pyrazole (5a)
1H NMR (CDCl3, 300 MHz) d 6.79 (d, J= 2.4 Hz, 1H, ArH),
7.09–7.12 (m, 1H, ArH), 7.30–7.38 (m, 3H, ArH), 7.45 (t,
J= 7.5 Hz, 2H, ArH), 7. 7.70 (d, J= 8.4 Hz, 2H, ArH),
7.79 (d, J= 8.4 Hz, 2H, ArH), 7.93–7.98 (m, 3H, ArH); 13C
NMR (CDCl3, 75 MHz) d 105.2, 119.3, 123.2, 125.0, 125.9,
126.8, 127.9, 128.1, 128.6, 128.7, 132.5, 132.9, 139.2, 143.4,
153.0; FABMS m/z (%): 303 (M++H, 100), 302 (M+, 68);
Anal. Calcd for C19H14N2S; C: 75.47; H: 4.67; N: 9.26; found:
C: 75.50; H: 4.65; N: 9.29.
2.3.2. 3-Phenyl-1-(4-(thiophen-3-yl)phenyl)-1H-pyrazole (5b)
1H NMR (CDCl3, 300 MHz) d 6.79 (d, J= 2.7 Hz, 1H, ArH),
7.35 (t, J= 7.2 Hz, 1H, ArH), 7.42–7.50 (m, 5H, ArH), 7.69Please cite this article in press as: Uramaru, N. et al., Synthesis and evaluation of in v
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7.93–7.98 (m, 3H, ArH); 13C NMR (CDCl3, 75 MHz) d
105.1, 119.3, 120.3, 125.9, 126.2, 126.5, 127.3, 127.9, 128.1,
128.7, 133.0, 134.0, 139.0, 141.3, 152.9; FABMS m/z (%):
303 (M++H, 100), 302 (M+, 71); Anal. Calcd for
C19H14N2S; C: 75.47; H: 4.67; N: 9.26; found: C: 75.43; H:
4.69; N: 9.23.
2.3.3. 1-(4-(Benzo[b]thiophen-2-yl)phenyl)-3-phenyl-1H-
pyrazole (5c)
1H NMR (CDCl3, 300 MHz) d 6.81 (d, J= 2.4 Hz, 1H, ArH),
7.30–7.38 (m, 3H, ArH), 7.45 (t, J= 7.8 Hz, 2H, ArH), 7.58
(s, 1H, ArH), 7.78–7.86 (m, 6H, ArH), 7.93 (t, J= 6.8 Hz,
2H, ArH), 8.00 (d, J= 2.4 Hz, 1H, ArH); 13C NMR (CDCl3,
75 MHz) d 105.4, 119.2, 119.6, 122.3, 123.6, 124.5, 124.6,
125.9, 127.4, 127.9, 128.2, 128.7, 123.9, 139.5, 139.8, 140.7,
143.1, 153.2; FABMS m/z (%): 353 (M++H, 100), 352
(M+, 59); Anal. Calcd for C23H16N2S; C: 78.38; H: 4.58; N:
7.95; found: C: 78.39; H: 4.61; N: 7.91.2.3.4. 1-(4-(Dibenzothiophen-4-yl)phenyl)-3-phenyl -1H-
pyrazole (5d)
1H NMR (CDCl3, 300 MHz) d 6.82 (d, J= 2.7 Hz, 1H, ArH),
7.38 (t, J= 7.2 Hz, 1H, ArH), 7.45–7.60 (m, 6H, ArH), 7.83–
7.86 (m, 3H, ArH), 7.92–8.02 (m, 5H, ArH), 8.16–8.22 (m, 2H,
ArH); 13C NMR (CDCl3, 75 MHz) d 105.3, 119.2, 120.6,
121.7, 122.6, 124.4, 125.1, 125.9, 126.8, 126.9, 128.0, 128.1,
128.7, 129.3, 133.0, 135.7, 136.0, 136.3, 138.4, 138.5, 139.4,itro bioactivity for polysubstituted N-arylpyrazole derivatives. Arabian Journal
Scheme 1
Synthesis and evaluation of in vitro bioactivity 5139.7, 153.1; FABMS m/z (%): 403 (M+ +H, 100), 402 (M+,
76); Anal. Calcd for C27H18N2S; C: 80.57; H: 4.51; N: 6.96;
found: C: 80.62; H: 4.56; N: 6.92.
2.3.5. 3,4-Diphenyl-1-(4-(thiophen-2-yl)phenyl)-1H-pyrazole
(6a)
1H NMR (CDCl3, 300 MHz) d 7.11 (t, J= 4.2 Hz, 1H, ArH),
7.30–7.35 (m, 10H, ArH), 7.60–7.63 (m, 2H, ArH), 7.72 (d,
J= 8.4 Hz, 2H, ArH), 7.81 (d, J= 8.7 Hz, 2H, ArH), 8.04
(s, 1H, ArH); 13C NMR (CDCl3, 75 MHz) d 119.1, 123.1,
123.2, 125.0, 126.4, 126.8, 127.0, 128.0, 128.1, 128.3, 128.4,
128.5, 128.7, 132.6, 132.7, 133.0, 138.9, 143.4, 150.6; FABMS
m/z (%): 379 (M++H, 100), 378 (M+, 47); Anal. Calcd for
C25H18N2S; C: 79.33; H: 4.79; N: 7.40; found: C: 79.35; H:
4.81; N: 7.45.
2.3.6. 3,4-Diphenyl-1-(4-(thiophen-3-yl)phenyl)-1H-pyrazole
(6b)
1H NMR (CDCl3, 300 MHz) d 7.30–7.38 (m, 8H, ArH), 7.42–
7.44 (m, 2H, ArH), 7.49–7.51 (m, 1H, ArH), 7.60–7.64 (m, 2H,
ArH), 7.71 (d, J= 8.4 Hz, 2H, ArH), 7.83 (d, J= 8.7 Hz, 2H,
ArH); 13C NMR (CDCl3, 75 MHz) d 119.2, 120.4, 123.0,
126.1, 126.4, 126.5, 127.0, 127.3, 127.9, 128.3, 128.4, 128.5,
128.7, 132.8, 133.0, 134.0, 138.7, 141.3, 150.5; FABMS m/z
(%): 379 (M++H, 100), 378 (M+, 69); Anal. Calcd for
C25H18N2S; C: 79.33; H: 4.79; N: 7.40; found: C: 79.34; H:
4.81; N: 7.39.
2.3.7. 1-(4-(Benzo[b]thiophen-2-yl)phenyl)-3,4-diphenyl-1H-
pyrazole (6c)
1H NMR (CDCl3, 300 MHz) d 7.32–7.39 (m. 10H, ArH), 7.58–
7.62 (m, 3H, ArH), 7.78–7.92 (m, 6H, ArH), 8.06 (s, 1H, ArH);
13C NMR (CDCl3, 75 MHz) d 119.1, 119.6, 122.3, 123.3,
123.6, 124.5, 124.6, 126.4, 127.0, 127.4, 128.0, 128.3, 128.4,Please cite this article in press as: Uramaru, N. et al., Synthesis and evaluation of in v
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150.8; FABMS m/z (%): 429 (M++H, 100), 428 (M+, 47);
Anal. Calcd for C29H20N2S; C: 81.28; H: 4.70; N: 6.54; found:
C: 81.26; H: 4.72; N: 6.51.
2.3.8. 1-(4-(Dibenzothiophen-4-yl)phenyl)-3,4-diphenyl -1H-
pyrazole (6d)
1H NMR (CDCl3, 300 MHz) d 7.36–7.39 (m, 8H, ArH), 7.47–
7.58 (m, 4H, ArH), 7.67 (t, J= 2.1 Hz, 2H, ArH), 7.84–7.88
(m, 3H, ArH), 7.95 (d, J= 8.7 Hz, 2H, ArH), 8.09 (s, 1H,
ArH), 8.19–8.22 (m, 2H, ArH); 13C NMR (CDCl3, 75 MHz)
d 119.1, 120.6, 121.7, 122.6, 123.1, 124.4, 125.1, 126.6, 126.8,
126.9, 127.0, 128.0, 128.3, 128.4, 128.5, 128.7, 129.3, 132.7,
133.0, 135.7, 135.9, 136.3, 138.4, 138.6, 139.3, 139.4, 150.6;
FABMS m/z (%): 479 (M++H, 100), 478 (M+, 41); Anal.
Calcd for C33H22N2S; C: 82.81; H: 4.63; N: 5.85; found: C:
82.82; H: 4.67; N: 5.88.
2.3.9. 1-Phenyl-3-(4-(thiophen-2-yl)phenyl)-1H-pyrazole (7a)
1H NMR (CDCl3, 300 MHz) d 6.79 (d, J= 2.4 Hz, 1H, ArH),
7.09–7.12 (m, 1H, ArH), 7.28–7.33 (m, 2H, ArH), 7.37 (d,
J= 3.6 Hz, 1H, ArH), 7.48 (t, J= 8.1 Hz, 2H, ArH), 7.68 (d,
J= 8.4 Hz, 2H, ArH), 7.77 (d, J= 7.8 Hz, 2H, ArH), 7.92–
7.97 (m, 3H, ArH); 13C NMR (CDCl3, 75 MHz) d 105.0,
119.1, 123.1, 124.8, 126.1, 126.2, 126.4, 128.1, 129.4, 132.2,
134.0, 140.2, 144.2, 152.4, 154.1; FABMS m/z (%): 303
(M++H, 100), 302 (M+, 35); Anal. Calcd for C19H14N2S;
C: 75.47; H: 4.67; N: 9.26; found: C: 75.45; H: 4.69; N: 9.31.
2.3.10. 1-Phenyl-3-(4-(thiophen-3-yl)phenyl)-1H-pyrazole
(7b)
1H NMR (CDCl3, 300 MHz) d 6.80 (d, J= 2.7 Hz, 1H, ArH),
7.30 (t, J= 7.2 Hz, 1H, ArH), 7.39–7.51 (m, 5H, ArH), 7.67itro bioactivity for polysubstituted N-arylpyrazole derivatives. Arabian Journal
Table 2 The inhibitory activity of the polysubstituted N-arylpyrazole derivatives 5a–d, 6a–d, and 7a–d.
Compounds GI50 (lM)
a,b
R1 R2 R3 NPC-TW01 NCI-H226 Jurkat
5a H Ph >50 >50 >50
5b H Ph >50 >50 >50
5c H Ph 34 >50 >50
5d H Ph 32 16 >50
6a Ph Ph 43 32 >50
6b Ph Ph >50 >50 >50
6c Ph Ph >50 >50 >50
6d Ph Ph >50 >50 >50
7a Ph H >50 >50 >50
7b Ph H >50 46 >50
7c Ph H >50 >50 >50
6 N. Uramaru et al.
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Table 2 (continued)
Compounds GI50 (lM)
a,b
R1 R2 R3 NPC-TW01 NCI-H226 Jurkat
7d Ph H 16 8.9 >50
N0-(4-formyl-1,3-diphenyl-1H-pyrazol-5-yl)-N,N- dimethyl-methanimidamide 31.4 9.3 23.5
a NCI-H226: human lung carcinoma; NPC-TW01: human nasopharyngeal carcinoma; Jurkat: human T-cell leukemia.
b All tested compounds were dissolved in 100% DMSO at a concentration of 20 mM as the stock solution. Cells were cultured without or in
the presence of the N-arylpyrazole derivatives at different concentrations for 72 h. Cell survival was determined by MTT assay. Drug molar
concentration causing 50% cell growth inhibition (GI50) was calculated. Each value represents the mean ± SD of three independent
experiments.
Synthesis and evaluation of in vitro bioactivity 7(d, J= 8.1 Hz, 2H, ArH), 7.79 (d, J= 7.8 Hz, 2H, ArH),
7.95–7.97 (m, 3H, ArH); 13C NMR (CDCl3, 75 MHz) d
105.0, 119.1, 120.2, 126.2, 126.3, 126.4, 126.6, 128.0, 129.4,
131.9, 135.4, 140.2, 142.0, 152.5, 154.3; FABMS m/z (%):
303 (M+ +H, 100), 302 (M+, 43); Anal. Calcd for
C19H14N2S; C: 75.47; H: 4.67; N: 9.26; found: C: 75.50; H:
4.871; N: 9.23.
2.3.11. 3-(4-(Benzo[b]thiophen-2-yl)phenyl)-1-phenyl-1H-
pyrazole (7c)
1H NMR (CDCl3, 300 MHz) d 6.82 (d, J= 2.7 Hz, 1H, ArH),
7.29–7.39 (m, 3H, ArH), 7.49 (t, J= 7.8 Hz, 2H, ArH), 7.61
(s, 1H, ArH), 7.78–7.90 (m, 6H, ArH), 7.97–8.02 (m, 3H,
ArH); 13C NMR (CDCl3, 75 MHz) d 105.1, 119.1, 119.4,
122.3, 123.5, 124.3, 124.5, 124.9, 126.3, 126.5, 126.7, 128.1,
129.3, 129.5, 133.0, 139.5, 140.1, 152.6; FABMS m/z (%):
353 (M+ +H, 100), 352 (M+, 24); Anal. Calcd for
C23H16N2S; C: 78.38; H: 4.58; N: 7.95; found: C: 78.40; H:
4.59; N: 7.92.
2.3.12. 3-(4-(Dibenzothiophen-4-yl)phenyl)-1-phenyl-1H-
pyrazole (7d)
1H NMR (CDCl3, 300 MHz) d 6.85 (d, J= 2.7 Hz, 1H, ArH),
7.32 (t, J= 7.5 Hz, 1H, ArH), 7.47–7.58 (m, 6H, ArH), 7.81–
7.88 (m, 5H, ArH), 7.99 (d, J= 2.7 Hz, 1H, ArH), 8.09 (d,
J= 8.4 Hz, 2H, ArH), 8.16–8.22 (m, 2H, ArH); 13C NMR
(CDCl3, 75 MHz) d 105.2, 119.0, 120.5, 121.7, 122.6, 124.3,
125.1, 126.2, 126.4, 126.7, 126.8, 128.1, 128.6, 129.4, 132.8,
135.8, 136.3, 136.7, 138.5, 139.6, 140.2, 152.5; FABMS m/z
(%): 403 (M++H, 100), 402 (M+, 28); Anal. Calcd for
C27H18N2S; C: 80.57; H: 4.51; N: 6.96; found: C: 80.54; H:
4.56; N: 6.94.
2.4. Antiproliferative activity
2.4.1. Cell lines
Human non-small cell lung carcinoma (NCI-H226), T-cell leu-
kemia (Jurkat) and nasopharyngeal carcinoma (NPC-TW01)Please cite this article in press as: Uramaru, N. et al., Synthesis and evaluation of in v
of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2014.12.004were purchased fromBioresource Collection andResearchCen-
ter (BCRC, Taiwan). All the tumor cell lines were maintained in
either RPMI-1640 or Modiﬁed essential medium (MEM)
supplied with 10% fetal bovine serum at 37 C in a humidiﬁed
atmosphere of 5% CO2/95% air in the presence of penicillin
and streptomycin.
2.4.2. Anti-proliferative efﬁcacy determination
Modiﬁed MTT method was used to determine the efﬁcacy of
anti-tumor activity and the GI50 value was calculated (Ref.).
Brieﬂy, logarithmic growth cells were seeded into 96-well
plates and were subsequently treated with vehicle or various
concentrations of tested compounds for 72 h. Two hours
before the end of the incubation, MTT (3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyl tetrazolium bromide) at a ﬁnal concen-
tration of 5 lg/ml was added. Afterward, solubilization
buffer (40% DMF and 20% SDS in H2O) was added to wells
to dissolve violet formazan precipitation for overnight at
37 C. The absorbance at 570 nm was then detected by a
microplate reader (Molecular Device, Sunnyvale, CA) and
the GI50 value was calculated by linear regression analysis
(Shia et al., 2011).
3. Result and discussion
3.1. Synthesis of fused thiophenyl/phenylpyrazoles and fused
benzothiophene/phenylpyrazoles 5a–d, 6a–d, and 7a–d
Scheme 1 shows the synthetic routes for the fused thiophenyl/
phenylpyrazole and benzothiophene/phenylpyrazole deriva-
tives 5a–d, 6a–d, and 7a–d. N1-Arylsydnones 1a and 1b were
prepared following the procedure developed by our laboratory
(Yeh et al., 1983). N1-Phenylsydnone 1a and N1-(p-bromophe-
nyl)sydnone 1b were reacted with acetylenes including phenyl-
acetylene, diphenylacetylene, and 1-bromo-4-ethynylbenzene
to give the corresponding 1,3-diaryl-1H-pyrazoles 2–4 as light
yellow solids in 47–74% yields (see Scheme 1, Dumitrascu
et al., 2002). In the smooth and regioselective 1,3-dipolar cycli-itro bioactivity for polysubstituted N-arylpyrazole derivatives. Arabian Journal
8 N. Uramaru et al.zation to synthesize compounds 2 and 4, two regioisomers with
pyrazolyl core can be individually accomplished (Chang et al.,
2006), except for compound 3. Identiﬁcation of regioisomers of
compounds 2 and 4 was made on the basis of its characteristic
1D 1H NMR spectrum. Particular attention was given to the
absorption of pyrazole proton. The ring proton (4-H) absorp-
tion of the 3-aryl-substituted isomers 2 and 4 moved 0.11–
0.12 ppm upﬁeld relative to the 3-H in the 4-aryl-substituted
isomers (Chang et al., 2006). In all cases, the ratios of a mixture
of pyrazole regioisomers (2 or 4) were obtained in 7/1 and 3-
aryl-substituted pyrazole isomers 2 and 4 were obtained as the
major products in 71% and 74% yields, respectively (see
Scheme 1). Another minor regioisomer of compounds 2 and 4
was also obtained in 11% and 12% yields, respectively
(Chang et al., 2006; Foster et al., 2011, 2012). Following the
previous literature, the substituted groups of alkynes were the
signiﬁcant factors for the regioselectivity in the cycloaddition
reaction (Foster et al., 2011, 2012).
1-(p-Bromophenyl)-3-phenyl-1H-pyrazole 2, 1-(p-bromo-
phenyl)-3,4-diphenyl-1H-pyrazole 3, and 1-phenyl-3-(p-
bromophenyl)-1H-pyrazole 4 were individually presented in
the palladium(0)-catalyzed cross-coupling reaction (Miyaura
and Suzuki, 1995) with fused-heterocycle boronic acids,
including 2-thiophenyl, 3-thiophenyl, 2-benzo[b]thiophenyl,
or dibenzothiophenyl-4-boronic acid (Qian et al., 1999). The
reaction mixture was accomplished by heating in a solution
of p-xylene/EtOH/aqueous potassium carbonate system. After
the reaction was completed, the normal work-up and puriﬁca-
tion were performed to give the corresponding polysubstituted
N-arylpyrazole products 5a–d, 6a–d, and 7a–d in 79–85%, 72–
85%, and 80–88% yields (see Table 1, and Scheme 1).3.2. Biological activity
Based on our previous literature reported data, 1,3-diphenyl-
1H-pyrazole analogs showed the remarkable potential antitu-
mor activity (Cheng et al., 2010; Wen et al., 2012; Huang
et al., 2012). Therefore, a set of polysubstituted N-arylpyraz-
oles 5a–d, 6a–d, and 7a–d compounds were synthesized to eval-
uate against a panel of human cancer cell lines in vitro,
including lung carcinoma (NCI-H226), nasopharyngeal
(NPC-TW01), and T-cell leukemia (Jurkat) cells. The GI50
value indicates the concentration of the compound that results
in a 50% decrease in the cell growth relative to the vehicle. To
test the substituted effect, the 1,5-disubstituted N-arylpyrazole
compounds 5a–d bearing with 2-thiophenyl, 3-thiophenyl, 2-
benzo[b]thiophenyl, or dibenzothiophenyl at the para-position
in N-1 phenyl of pyrazolic ring were preliminarily evaluated.
Following the inhibitory results, 2-benzo[b]thiophenylpyrazole
5c and 1-[3-(4-dibenzothienyl)phenyl]-4-phenyl-1H-pyrazole
5d showed the better inhibitory activity against NCI-H226
cancer cell (32–34 lM, see Table 2). Particularly, 1-[3-(4-dib-
enzothienyl)phenyl]-4-phenyl-1H-pyrazole 5d also possessed
signiﬁcant inhibition for lung carcinoma cells (NCI-H226,
16 lM, Table 2).
For the further SAR study, a series of trisubstituted N-aryl-
pyrazoles 6a–d with introducing a phenyl group at C-4 posi-
tion on pyrazolic ring was used as the comparing model (see
Table 2). Based on the biological activity data of compound
6a–d, only compound 6a possessed the negligible inhibitory
activity against NPC-TW01 (43 lM) and NCI-H226 (32 lM,Please cite this article in press as: Uramaru, N. et al., Synthesis and evaluation of in v
of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2014.12.004see Table 2). This experimental result indicated the gifting phe-
nyl group at C-4 position on pyrazolic ring was not promoted
the inhibitory activity.
Based on the inhibition result between compounds 5a–d
and compounds 6a–d, we consequently introduced thiophenyl,
benzothiophenyl and dibenzothiophenyl groups toward the
para-position of C-3 phenyl moiety and removed C-4 phenyl
group in the pyrazolic ring. Among others, compounds 7a–d
showed poor inhibitory potency against three cancer cell lines,
except for dibenzothiophenyl/phenylpyrazole 7d. Compound
7d showed signiﬁcant inhibition against lung carcinoma cell
(NCI-H226, 16 lM, Table 2) and nasopharyngeal cell (NPC-
TW01, 8.9 lM, see Table 2). As a result, dibenzothiophenyl
group was regarded as the best active bioisostere to be intro-
duced into the phenylpyrazole core molecule for the construc-
tion of the potent lead compounds. In the other hand,
compounds 5d and 7d seemed to possess the signiﬁcant inhib-
itory activity for NPC-TW01 and NCI-H226 two cancer cells,
particularly for NCI-H226.
Following the data presented in Table 2 and our previous
research results (Cheng et al., 2010; Wen et al., 2012; Huang
et al., 2012), we could arrive at the conclusion that the activity
of the tested compounds may be correlated to the variation and
modiﬁcations of structure. For example, the substituents on the
C-4 position of pyrazolic ring were not suitable for the antitu-
mor activity comparing to other positions. In addition, change
of substituents of para-phenyl on the N-1 or C-3 position of
pyrazolic ring could also affect the activities of these com-
pounds. A comparison of the para-substituents on the N-1 or
C-3 phenyl demonstrated that dibenzothiophenyl group could
dramatically improve anti-proliferative activity, particularly
on the C-3 phenyl group. On the basis of our previous research,
it was revealed that the class of 1H-pyrazol-5-yl-N,N-dimethyl-
formamidines inhibitors possessed exclusively better anti-can-
cer inhibitory activity than 1,3-diphenyl-1H-pyrazoles,
especially for NPC-TW01 and Jurkat (Cheng et al., 2010).
4. Conclusion
A series of polysubstituted N-arylpyrazole derivatives were
synthesized from N1-arylsydnone with acetylene and boronic
acid via 1,3-dipolar cycloaddition and Suzuki coupling reac-
tion. 2-Thiophenyl, 3-thiophenyl, 2-benzo[b]thiophenyl, and
dibenzothiophenyl groups were introduced into the N-arylpy-
razole core as the bioisosteres. Following the structure–activity
relationship study, 4-dibenzothiophenyl group was regarded as
the best active bioisostere for the improvement of the inhibi-
tory activity. Furthermore, compounds 5d and 7d with dib-
enzothiophenyl moiety possessed the signiﬁcant inhibitory
activity for NPC-TW01 (32 lM and 16 lM) and NCI-H226
(16 lM and 8.9 lM) two cancer cells, respectively.Acknowledgments
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